bioRxiv Science⌕ Search

Biology subjects

Shimozawa, M.

Publications and source records attributed to Shimozawa, M..

2 recordsLinked to original sources

Early mitochondrial dysfunction proceeds neuroinflammation, synaptic alteration, and autophagy impairment in hippocampus of App knock-in Alzheimer mouse models

Increased amyloid {beta}-peptide (A{beta}) level is one of the drivers of Alzheimers disease (AD). Amyloid precursor protein (App) knock-in mice recapitulate the human A{beta} pathology, allowing the elucidation of the downstream effects of A{beta} and their temporal appearance upon disease progression. Here we have investigated the sequential onset of AD-like pathologies in the AppNL-F and AppNL-G-F knock-in mouse models by time-course transcriptome analysis of the hippocampus, a region severely affected in AD. Energy metabolism emerged as one of the most significantly altered pathways at an early stage of the development of the pathologies. Functional experiments in mitochondria isolated from AppNL-G-F brain subsequently identified upregulation of oxidative phosphorylation driven by the activity of mitochondrial complexes I, IV and V, combined with higher susceptibility to Ca2+-overload. This was followed by a strong neuroinflammatory response and impaired autophagy. Accumulation of autophagosomes and reduced number of mitochondria content in presynaptic terminals could account for the altered synapse morphology including increased number of synaptic vesicles and lowered thickness of post synaptic density in AppNL-G-F mice. This shows that A{beta}-induced pathways in the App knock-in mice recapitulate some key pathologies observed in AD brain, and our data herein contributes to the understanding of their timewise appearance and potential role in new therapeutic approaches.

neuroscience↗

Somatostatin receptor subtypes 1 and 4 redundantly regulate neprilysin, the major amyloid beta-degrading enzyme, in brain

Alzheimers disease (AD) brains are characterized by increased levels of the pathogenic amyloid beta (A{beta}) peptide, which accumulates into extracellular plaques. Finding a way to lower A{beta} levels is fundamental for the prevention and treatment of AD. Neprilysin is the major A{beta} degrading enzyme which is regulated by the neuropeptide somatostatin. Here we used a combination of in vitro and in vivo approaches to identify the subtype specificity of the five somatostatin receptors (SSTs) expressed in the brain, involved in the regulation of neprilysin. Using a battery of Sst double knockout (dKO) mice we show that neprilysin is regulated by SST1 and SST4 in a redundant manner. Sst1 and Sst4 dKO mice exhibit a specific decrease of presynaptic neprilysin in the Lacunosum molecular layer. Moreover, a genetic deficiency of Sst1 and Sst4 in amyloid beta precursor protein (App) knock-in mice, an AD mouse model, aggravates the A{beta} pathology in the hippocampus. As a first proof of concept towards an A{beta}-lowering strategy involving neprilysin, we demonstrate that treatment with an agonist selective for SST1 and SST4 ameliorates the A{beta} pathology and improves cognition in the App knock-in AD mouse model.

neuroscience↗